VX-478 protease inhibitor data

Partner Glaxo Wellcome presented data on VRTX's VX-478 protease inhibitor at the International Conference on Antiviral Research in Fukushima, Japan. Glaxo discussed data from an ongoing Phase I/II trial, in which patients are treated for 28 days at doses of 300 mg twice/day, 300 mg three times/day, 900 mg twice/day and 1200 mg twice/day.

Data from the first cohort of 10 patients treated at the 300 mg twice/day dose had a concentration of drug at the trough (just prior to the next dose) in excess of the IC90 (the concentration of drug that eliminates 90 percent of viral replication in vitro). Peak concentrations averaged >30 times IC90. Half-life was about 9 hours. ...